Cite
MLA Citation
Doreen Jackson et al.. “Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine.” Journal for immunotherapy of cancer, vol. 3, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100137781007.0x000003